Iron toxicity: Relevance for dialysis patients

Nephrology Dialysis Transplantation

Volumn 29, Issue 2, 2014, Pages 255-259

  Fishbane, Steven ^a   Mathew, Anna ^a   Vaziri, Nosratola D ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anemia; iron; toxicity

Indexed keywords

FERRIC GLUCONATE; FERRITIN; FERROPORTIN; HEMOGLOBIN; HEPCIDIN; IRON DERIVATIVE; IRON DEXTRAN; IRON SACCHARATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; TRANSFERRIN BLOOD LEVEL;

ANEMIA; IRON; TOXICITY;

ANEMIA, IRON-DEFICIENCY; DIETARY SUPPLEMENTS; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; IRON COMPOUNDS; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC; PREVALENCE; RENAL DIALYSIS; RISK FACTORS; WORLD HEALTH;

EID: 84896719456     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft269     Document Type: Review

References (44)

1. Eschbach JW, Cook JD, Scribner BH et al. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87: 710-713
2. Kopelman RC, Smith L, Peoples L et al. Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial Int 2007; 11: 238-246
3. Ford BA, Coyne DW, Eby CS et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009; 75: 104-110
4. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999; 34: 21-28
5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for anemia in chronic kidney disease. Kidney Int 2012; 2(Suppl): 279-335
6. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-46
7. Allegra V, Mengozzi G, Vasile A. Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 1991; 57: 175-182
8. Li H, Wang S-X. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif 2008; 26: 151-156
9. Macdougall I, Tucker B, Thompson J. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
10. Nissenson AR, Lindsay RM, Swan S et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 1999; 33: 471-482
11. Coyne DW, Kapoian T, Suki Wet al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
12. Nairz M, Theurl I, Ludwiczek S et al. The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol 2007; 9: 2126-2140
13. Rostoker G, Griuncelli M, Loridon C et al. Hemodialysis-Associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study. Am J Med 2012; 125: 991-999
14. Canavese C, Bergamo D, Ciccione G et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098
15. Ali M, Fayemi AO, Rigolosi R et al. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 1980; 244: 343-345
16. Kooistra MP, Kersting S, Gosriwatana I et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32 (Suppl 1): 36-41
17. Rooyakers T, Stroes E, Kooistra M et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32(Suppl 1): 9-16
18. Vaziri ND. Understanding iron: Promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013. doi: 10.1053/j.ajkd.2012.10.027
19. Kell DB. Iron behaving badly: Inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genom 2009; 2: 2
20. Kamanna VS, Ganji SH, Shelkovnikov S et al. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2011; 35: 114-119
21. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004; 5: 1802-1809
22. Zhou XJ, Laszik Z, Wang XQ et al. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000; 80: 1905-1914
23. Salahudeen A, Oliver B, Bower J et al. Increase in plasma esterified F2 isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001; 60: 1525-1531
24. Tovbin D, Mazor T, Vorobiov M et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 2002; 40: 1005-1012
25. Pai AB, Conner T, McQuade CR et al. Non-Transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011; 24: 603-613
26. Roob J, Khoschsorur G, Tiran A et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549
27. Agarwal R, Leehey DJ, Olsen SM et al. Proteinuria induced by parenteral iron in chronic kidney disease-A comparative randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6: 114-121
28. Carlini R, Alonzo E, Belloni-Font E et al. Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. Nephrol Dial Transplant 2006; 21: 3055-3056
29. Stanley N, Stadler N, Woods AA et al. Concentrations of iron correlate with the extent of protein, but not lipid, oxidation in advanced human atherosclerotic lesions. Free Radic Biol Med 2006; 40: 1636-1643
30. Lapenna D, Pierdomenico SD, Ciofani G et al. Association of body iron stores with low molecular weight iron and oxidant damage of human atherosclerotic plaques. Free Radic Biol Med 2007; 42: 492-498
31. Porreca E, Ucchino S, Di Febbo C et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994; 14: 299-304
32. Drüeke T,Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
33. Van Der Weerd NC, Grooteman MP, Bots ML et al. CONTRAST Investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. Epub ahead of print November 19, 2013.
34. Kapoor M, Schleinitz MD, Gemignani A et al. Outcomes of patients with chronic heart failure and iron deficiency treated with intravenous iron: A meta-Analysis. Cardiovasc Hematol Disord Drug Targets 2013; 13: 35-44
35. Hoen B, Kessler M, Hestin D et al. Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377-381
36. Hoen B, Paul-Dauphin A, Hestin D et al. MEPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876
37. Djeha A, Brock JH. Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes. Biochem Biophys Acta 1992; 1133: 147-152
38. Liu JH, Liu YL, Lin HH et al. Intravenous iron attenuates postvaccination anti-HBsAg titers after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. Int J Clin Pract 2009; 63: 387-393
39. Gupta A, Zhuo J, Zha J et al. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol 2010; 11:16
40. Deicher R, Ziai F, Cohen G et al. High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736
41. Van Asbeck BS, Marx JJ, Struyvenberg A et al. Functional defects in phagocytic cells from patients with iron overload. J Infect 1984; 8: 232-240
42. Ichii H, Masuda Y, Hassanzadeh T et al. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol 2012; 36: 50-57
43. Parkkinen J, von Bonsdorff L, Peltonen S et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after IV iron-saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834
44. Fuller DS, Pisoni RL, Bieber BA et al. The DOPPS Practice Monitor for US dialysis care: Trends through December 2011. Am J Kidney Dis. 2013; 61: 342-346